Results 241 to 250 of about 7,389,456 (292)
Immunity, 2020 Tumor immune escape limits durable responses to T cell therapy. Here, we examined how regulation and function of gene products that provide the target epitopes for CD8 T cell anti-tumor immunity influence therapeutic efficacy and resistance.
Mark J. Smyth +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Adoptive cell therapies in thoracic malignancies
Cancer Immunology, Immunotherapy, 2022Immunotherapy has gained great interest in thoracic malignancies in the last decade, first in non-small cell lung cancer (NSCLC), but also more recently in small-cell lung cancer (SCLC) and malignant pleural mesothelioma (MPM). However, while 15-20% of patients will greatly benefit from immune checkpoint blockers (ICBs), a vast majority will rapidly ...
Julie Lasvergnas +5 more
openaire +2 more sources
Adoptive T cell cancer therapy
Nature Materials, 2018Tumour heterogeneity and off-target toxicity are current challenges of cancer immunotherapy. Karine Dzhandzhugazyan, Per Guldberg and Alexei Kirkin discuss how epigenetic induction of tumour antigens in antigen-presenting cells may form the basis for multi-target therapies.
Karine N, Dzhandzhugazyan +2 more
openaire +2 more sources
2021
Therapy in oncology has undergone a revolution in recent years. New biological agents targeting specific intra- and extracellular domains have become standard of care, immunotherapy with checkpoint inhibitors revolutionized therapy in Melanoma, Renal Cell Carcinoma, and in Non-Small Cell Lung Cancer and combinations of both are now entering clinical ...
openaire +1 more source
Therapy in oncology has undergone a revolution in recent years. New biological agents targeting specific intra- and extracellular domains have become standard of care, immunotherapy with checkpoint inhibitors revolutionized therapy in Melanoma, Renal Cell Carcinoma, and in Non-Small Cell Lung Cancer and combinations of both are now entering clinical ...
openaire +1 more source
Adoptive cell therapies for posttransplant infections
Current Opinion in Oncology, 2019Purpose of review Viral and fungal infections cause significant morbidity and mortality following hematopoietic stem-cell transplantation (HSCT), primarily due to the prolonged and complex immunodeficient state that results from conditioning chemo-radiotherapy and subsequent prophylaxis of graft vs. host disease.
Gaurav, Sutrave, David J, Gottlieb
openaire +2 more sources
Adoptive cell transfer therapy for melanoma
Experimental Dermatology, 2022AbstractAdoptive cell transfer (ACT) of tumor‐infiltrating lymphocytes (TILs) for melanoma is an example of the most successful cancer immune therapy. It achieves a durable complete response about ~20% of patients, and they might be cured. However, the ratio of patients with durable benefits is not high, and its complicated procedure prevents its ...
openaire +2 more sources
Seminars in hematology, 1999
Adoptive immunotherapy, or the transfer of immunocompetent cells, has been shown to be a promising new strategy for treatment of a variety of malignancies, including leukemia and non-Hodgkin's lymphoma. The possibility that it may likewise benefit patients with multiple myeloma is now being explored by researchers in Europe and the United States.
Lokhorst, H.M., Liebowitz, D.
openaire +2 more sources
Adoptive immunotherapy, or the transfer of immunocompetent cells, has been shown to be a promising new strategy for treatment of a variety of malignancies, including leukemia and non-Hodgkin's lymphoma. The possibility that it may likewise benefit patients with multiple myeloma is now being explored by researchers in Europe and the United States.
Lokhorst, H.M., Liebowitz, D.
openaire +2 more sources
Adoptive Cell Therapy for Metastatic Melanoma
The Cancer Journal, 2017Adoptive cell therapy (ACT) of tumor-infiltrating lymphocytes (TILs) is a powerful form of immunotherapy by inducing durable complete responses that significantly extend the survival of melanoma patients. Mutation-derived neoantigens were recently identified as key factors for tumor recognition and rejection by TILs.
Efrat, Merhavi-Shoham +4 more
openaire +2 more sources
Adoptive cell therapy in multiple Myeloma
Expert Opinion on Biological Therapy, 2017Recent breakthrough advances in Multiple Myeloma (MM) immunotherapy have been achieved with the approval of the first two monoclonal antibodies, elotuzumab and daratumumab. Adoptive cell therapy (ACT) represents yet another, maybe the most powerful modality of immunotherapy, in which allogeneic or autologous effector cells are expanded and activated ex
Sonia, Vallet +2 more
openaire +2 more sources